Many lifestyle-related diseases are thought to share a background of oxidative stress and chronic low-grade inflammation. Obesity, insulin resistance, cardiovascular disease, metabolic syndrome, diabetes, cancer, and neurodegenerative diseases such as Parkinson’s disease and Alzheimer’s disease may appear unrelated, yet research suggests that some of their underlying biological processes overlap.
This has increased interest in naturally derived compounds that may act on multiple biological pathways and have relatively low toxicity. This article examines a 2024 review in Nutrients that organized research on hexaraphane/6-MSITC, a compound derived from Japanese wasabi. The review evaluated why hexaraphane/6-MSITC has been proposed as a research candidate in cancer, Alzheimer’s disease, and obesity by examining its effects on cellular signaling pathways.
- Insulin resistance
- A state in which cells respond less effectively to insulin, the hormone that lowers blood glucose.
- Signaling pathway
- A sequence of molecular events through which a cell receives information, transmits it internally, and produces a response.
What You Will Learn
- How a 2024 review organized hexaraphane/6-MSITC research across cancer, neurodegenerative disease, and obesity
- Why modulation of multiple signaling pathways, centered on Nrf2/Keap1, may be relevant across these different research areas
- Why the evidence must be interpreted cautiously: most findings come from cell and animal studies, while human clinical research remains limited
What Is Hexaraphane/6-MSITC?
Hexaraphane/6-MSITC is a relatively uncommon bioactive compound found in the rhizome of Japanese wasabi, Eutrema japonicum. It belongs to the isothiocyanate family and has a structure similar to sulforaphane, the compound widely studied in broccoli sprouts. Experimental studies have reported antioxidant and anti-inflammatory activity, along with relatively low toxicity compared with some synthetic compounds.
- Isothiocyanates
- A group of pungent compounds found in cruciferous vegetables such as wasabi and broccoli.
The Review Examined in This Article
The paper discussed here is a review published in Nutrients in 2024 by Bartkowiak-Wieczorek and colleagues. The authors searched multiple databases and collected research on wasabi, wasabi extracts, and hexaraphane/6-MSITC.
- Review article
- A paper that collects and organizes previously published studies to summarize the state of a field and identify unanswered questions. It does not present a new experiment of its own.
The paper synthesized previously published cell studies, animal studies, and a small number of human trials. The strength of evidence differs among these study types, so its conclusions should be interpreted as hypotheses and research possibilities rather than established preventive or therapeutic effects.
A Common Mechanistic Link: Nrf2 as a Cellular Defense Regulator
Why might a single compound attract attention in cancer, neurodegeneration, and metabolism? One answer proposed by the review is that hexaraphane/6-MSITC affects several signaling pathways. The central pathway is Nrf2/Keap1–ARE signaling.
Nrf2 is a protein that coordinates cellular defenses against oxidative stress. Under basal conditions, it is restrained by Keap1. Oxidative stress modifies this regulation, allowing Nrf2 to become active. Nrf2 then induces groups of genes involved in antioxidant defense and detoxification. Experimental studies have reported that hexaraphane/6-MSITC stabilizes Nrf2 and increases cellular defense responses. For a detailed explanation, see What Is Nrf2?.
The review also described research on pathways involved in energy metabolism, including AMPK; lipid metabolism, including PPAR; cell proliferation; inflammation; and cancer biology. Simultaneous effects across several pathways may help explain the range of experimental findings.
- AMPK
- An enzyme that senses cellular energy status and regulates metabolism; it is often described as an energy sensor.
- PPARγ
- A protein involved in lipid metabolism and adipocyte function.
A NOMON & Co. Scientist’s Perspective
The interest in hexaraphane/6-MSITC across apparently different diseases may reflect its action on Nrf2, a regulator upstream of oxidative-stress and inflammatory responses. Many compounds, including vitamin C and β-carotene, have antioxidant properties, but they are cleared within hours. Some studies suggest that the biological response to hexaraphane/6-MSITC may persist longer, although the duration and clinical relevance require further study. In that sense, the compound has been compared to a security system that remains on duty.
Research Areas Highlighted in the Review
The review organized the findings into three broad areas.
1. Cancer, Including Breast and Colorectal Cancer
Breast cancer: In experiments using human breast cancer cell lines, hexaraphane/6-MSITC induced apoptosis, or programmed cell death, in a concentration-dependent manner in a breast cancer subtype considered difficult to treat. The proposed mechanism involved simultaneous suppression of signaling related to inflammation and cell proliferation. The same effect was not observed in another breast cancer cell line, MCF-7, indicating that responses may differ among cancer types1.
Colorectal cancer: Studies in human colorectal cancer cells reported that hexaraphane/6-MSITC activated signaling associated with apoptosis2 and disrupted mitochondrial function, leading to cell death. The effect was observed regardless of whether the tumor-suppressor protein p53 was functional, raising the hypothesis that the compound could act in cells with impaired p533.
Other experimental studies have reported inhibition of certain cytochrome P450 enzymes that can activate carcinogens, prompting interest in possible effects on carcinogenesis. These are cell-based findings and do not demonstrate cancer prevention or treatment in humans.
2. Neurodegenerative Diseases, Including Alzheimer’s and Parkinson’s Disease
Alzheimer’s disease: In a mouse model produced by injecting amyloid-β into the brain, administration of 5 mg/kg of hexaraphane/6-MSITC for 10 days improved performance in a passive-avoidance memory test. In the hippocampus, treatment attenuated the amyloid-β-associated decline in glutathione, the increase in reactive oxygen species, neuroinflammation, and apoptosis4.
- Amyloid-β
- A peptide that can accumulate in the brain and is considered one component of Alzheimer’s disease pathology.
Parkinson’s disease: In mice given the neurotoxin 6-OHDA to create Parkinson’s-like pathology, hexaraphane/6-MSITC showed neuroprotective effects and reduced motor impairment5.
The researchers proposed that Nrf2 activation contributed to both sets of findings. The relationship with Alzheimer’s disease is also discussed in this NOMON & Co. article.
3. Obesity and Metabolic Syndrome
In rats prone to metabolic syndrome, administration of wasabi leaf extract at 4 g/kg/day attenuated weight gain and hypertension and significantly lowered blood triglycerides. The proposed mechanism involved suppression of PPARγ, reduced adipocyte hypertrophy, and increased adiponectin, leading to AMPK activation and changes in lipid metabolism and liver-related measures6.
This study used wasabi leaf extract rather than purified hexaraphane/6-MSITC. Its findings therefore cannot be attributed to hexaraphane/6-MSITC alone. The results suggest that effects on AMPK may contribute to metabolic changes in this model.
Figure: Proposed effects of hexaraphane/6-MSITC on multiple signaling pathways. Simultaneous modulation of Nrf2/Keap1, AMPK, PPAR, and other pathways has been proposed as the basis for its diverse experimental effects. Up arrows indicate activation or increases; down arrows indicate inhibition or decreases. Source: Bartkowiak-Wieczorek J. et al., Nutrients 16(15), 2509 (2024), adapted from Fig. 2.
How Far Has Human Research Progressed?
Most of the findings described above come from cell and animal studies. As the review repeatedly emphasized, human evidence remains limited.
Human reports available at the time included:
- A double-blind randomized controlled trial in healthy adults aged 60 and older reported improvements in working memory and episodic memory7. See Hexaraphane/6-MSITC and Memory in Older Adults.
- An open-label study in people with ME/CFS reported pre-post changes in cognition, brain fog, and pain8. See Hexaraphane/6-MSITC in ME/CFS.
- A study in healthy participants using 16 mg/day for four weeks reported no notable adverse events and changes in fatigue and sleep quality9.
- Double-blind randomized controlled trial
- A study in which participants are randomly assigned to groups and neither participants nor assessors know who receives the active intervention. This design reduces expectation-related bias.
- Working memory
- The temporary storage and manipulation of information needed during a task.
- Episodic memory
- Memory for events, including what happened, where, and when.
- Open-label trial
- A study in which both participants and researchers know what intervention is being administered.
These studies provide early human data, but their sample sizes and designs have limitations. Larger, rigorously controlled trials are necessary to establish reproducibility, effective doses, safety, and clinical significance.
Significance of the Review and Future Directions
The review’s main contribution was to organize a fragmented body of research through the shared perspective of signaling pathways. This structure helps explain why hexaraphane/6-MSITC is being studied across several disease areas.
The synthesis may also help identify priorities for future human studies, including which conditions, doses, and outcomes should be tested. Human data on memory, fatigue, and sleep are beginning to appear, but the field remains at the stage of testing, one by one, whether possibilities identified in basic research translate into meaningful effects in people.
Summary
Hexaraphane/6-MSITC from Japanese wasabi affects several signaling pathways in experimental systems, centered on Nrf2/Keap1. Cell and animal studies have examined it in cancer, neurodegenerative disease, and obesity or metabolic dysfunction.
However, most of the evidence remains preclinical. Human trials are limited, and the findings do not establish that hexaraphane/6-MSITC prevents or treats cancer, Alzheimer’s disease, Parkinson’s disease, obesity, or other conditions. Research is continuing to determine whether observations made in cells and animals can be reproduced safely and meaningfully in humans.
References
- Fuke, Y. et al. "Wasabi-derived 6-(methylsulfinyl)hexyl isothiocyanate induces apoptosis in human breast cancer by possible involvement of the NF-κB pathways." Nutr. Cancer 66(5), 879-887 (2014). ↩
- Yano, S. et al. "Involvement of ERK1/2-mediated ELK1/CHOP/DR5 pathway in 6-(methylsulfinyl)hexyl isothiocyanate-induced apoptosis of colorectal cancer cells." Biosci. Biotechnol. Biochem. 83(5), 960-969 (2019). ↩
- Yano, S. et al. "Wasabi 6-(methylsulfinyl)hexyl isothiocyanate induces apoptosis in human colorectal cancer cells through p53-independent mitochondrial dysfunction pathway." BioFactors 44(3), 273-282 (2018). ↩
- Morroni, F. et al. "Protective Effects of 6-(Methylsulfinyl)hexyl Isothiocyanate on Aβ1-42-Induced Cognitive Deficit, Oxidative Stress, Inflammation, and Apoptosis in Mice." Int. J. Mol. Sci. 19(7), 2083 (2018). ↩
- Morroni, F. et al. "Neuroprotection by 6-(methylsulfinyl)hexyl isothiocyanate in a 6-hydroxydopamine mouse model of Parkinson's disease." Brain Res. 1589, 93-104 (2014). ↩
- Oowatari, Y. et al. "Wasabi leaf extracts attenuate adipocyte hypertrophy through PPARγ and AMPK." Biosci. Biotechnol. Biochem. 80(8), 1594-1601 (2016). ↩
- Nouchi, R. et al. "Benefits of Wasabi Supplements with 6-MSITC on Memory Functioning in Healthy Adults Aged 60 Years and Older." Nutrients 15(21), 4608 (2023). ↩
- Oka, T. et al. "Clinical effects of wasabi extract containing 6-MSITC on myalgic encephalomyelitis/chronic fatigue syndrome: an open-label trial." Biopsychosoc. Med. 16, 26 (2022). ↩
- Nakajima, R. et al. "Oral administration of 6-methylsulfinylhexyl isothiocyanate extracted from wasabi is safe and improves the fatigue and sleep of healthy volunteers." (2023). PMID: 37612759. ↩
